Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share. Harpoon Therapeutics expects that th...
Gainers: [[SOS]] +63.9%. [[XNET]] +23.7%. [[TEN]] +11.2%. [[CERS]] +8.9%. [[SITM]] +8.3%.Losers: [[GBTC]] -8.9%. [[PLYA]] -7.5%. [[UUU]] -6.5%. [[INN]] -6.4%. [[HARP]] -5.8%. For further details see: SOS, XNET, UUU and PLYA among after-hours movers
Harpoon Therapeutics (HARP) commences an underwritten public offering of its common stock.Underwriters option to purchase up to an additional 15% of the number of shares sold.Net proceeds of the offering, together with other available funds, to fund the continued clinical development of ...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connect...
Harpoon Therapeutics (HARP) has dosed the first patient with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer ((SCLC)) and other tumors associated with DLL3 expression.The trial plans to enroll pati...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targ...
Harpoon Therapeutics presents an opportunity in the cancer treatment space, and at the current levels, the stock is a good buy. HPN424, HARP’s most advanced product, targets prostate cancer, which alone presents an opportunity of over $5 billion. HARP’s attraction, a...
Harpoon Therapeutics ([[HARP]] +3.7%) has reported a confirmed partial response for its most advanced program, HPN424 in Phase 1/2a study for the treatment of metastatic castration-resistant prostate cancer.At the highest fixed dose tested to date, 160ng/kg, one patient out of 7 showed c...
HPN424 has show n confir med partial response in treatment of metastatic castration - resistant prostate cancer in highest fixed dose cohort (160 ng/kg) of continuing Phase 1 /2a d o se escalation trial Thre...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a cl...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NASDAQ Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...